BORYUNG CORPORATION – Trademark Portfolio
Entity Type: 03
BORYUNG CORPORATION holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include CARE IN SPACE, HUMANS IN SPACE, CARE IN SPACE CHALLENGE, and HUMANS IN SPACE 2ND GLOBAL CARE IN SPACE INITIATIVE. The owner is based in SEOUL.
136 CHANGGYEONGGUNG-RO, JONGNO-GU,
SEOUL 03127 , KR
Showing of trademarks Trademarks
Trademark Classifications
BORYUNG CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BORYUNG CORPORATION have?
BORYUNG CORPORATION has 9 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned.
What trademark classes does BORYUNG CORPORATION file in?
BORYUNG CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are BORYUNG CORPORATION's most well-known trademarks?
BORYUNG CORPORATION's registered trademark portfolio includes well-known marks such as CARE IN SPACE, HUMANS IN SPACE, CARE IN SPACE CHALLENGE, and HUMANS IN SPACE 2ND GLOBAL CARE IN SPACE INITIATIVE. These are among 5 currently registered trademarks in the portfolio.
What is BORYUNG CORPORATION's trademark registration success rate?
BORYUNG CORPORATION has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.